v3.26.1
Consolidated Statements of Changes in Equity (Deficit) - USD ($)
shares in Thousands, $ in Thousands
Issued capital [member]
Stock Option Reserve [Member]
Treasury Stock [Member]
Accumulated Other Comprehensive Income Loss [Member]
Retained earnings [member]
Equity attributable to owners of parent [member]
Non-controlling interests [member]
Total
Beginning balance, value at Mar. 31, 2023 $ 218,782 $ 21,204 $ (4,325) $ (159,616) $ 76,045 $ (650) $ 75,395
Begnning balance, shares at Mar. 31, 2023 880              
IfrsStatementLineItems [Line Items]                
Balance, April 1, 2022 (Pre-Split), shares 17,606              
Share-based compensation expense 2,637 2,637 2,637
Shares issued under Registered Direct Offering
Shares issued under Registered Direct Offering, shares 98              
Shares issued related to the ATM agreement, net of share issuance costs $ 662 662 662
Shares issued related to the ATM agreement, net of share issuance costs , shares 9              
Shares issued or accrued for services $ 50 50 50
Shares issued or accrued for services, shares 1              
Shares issued pursuant to distribution of restricted stock units $ 5 5 5
Shares issued pursuant to distribution of restricted stock units, shares 1              
Derecognition of investment in public company 4,363 (4,363)
Net unrealized loss on investments (38) (38) (38)
Net loss for the year (75,339) (75,339) (43) (75,382)
Treasury stock obtained in exchange for return of investment interest to Compedica              
Ending balance, value at Mar. 31, 2024 $ 219,499 23,841 (239,318) 4,022 (693) 3,329
Ending Balance, shares at Mar. 31, 2024 989              
IfrsStatementLineItems [Line Items]                
Share-based compensation expense 321 321 321
Shares issued pursuant to distribution of restricted stock units $ 30 30 30
Shares issued pursuant to distribution of restricted stock units, shares 9              
Net unrealized loss on investments              
Net loss for the year (6,767) (6,767) (11) (6,778)
Correction of prior period overstated share-based compensation expense (632) 632
Shares issued under private placement, net of share issuance costs $ 2,150 2,150 2,150
Shares issued under private placement, net of share issuance costs, shares 524              
Pre-Funded warrants exercised $ 1 1 1
Pre-Funded warrants exercised, shares 60              
Additional round up shares issued for fractional shares in connection with 1-for-20 reverse share split  
Additional round up shares issued for fractional shares in connection with 1-for-20 reverse stock split, shares 52              
Shares issued for accrued bonuses $ 120 120 120
Shares issued accrued for bonuses, shares 19              
Treasury stock obtained in exchange for return of investment interest to Compedica              
Ending balance, value at Mar. 31, 2025 $ 221,800 23,530 (245,453) (123) (704) (827)
Ending Balance, shares at Mar. 31, 2025 1,653              
IfrsStatementLineItems [Line Items]                
Share-based compensation expense 1,745 1,745 1,745
Shares issued related to the ATM agreement, net of share issuance costs $ 12,030 12,030 12,030
Shares issued related to the ATM agreement, net of share issuance costs , shares 4,063              
Net unrealized loss on investments              
Net loss for the year (38,626) (38,626) (1) (38,627)
Shares issued under private placement, net of share issuance costs and put rights $ 14,535 14,535 14,535
Shares issued under private placement, net of share issuance costs and put rights , shares 3,416              
Shares issued relating to the acquisition of Compedica $ 5,000 5,000 5,000
Shares issued relating to the acquisition of Compedica, shares 625              
Shares issued under registered direct offering, net of share issuance costs $ 12,688 12,688 12,688
Shares issued under registered direct offering, net of share issuance costs , shares 5,230              
Exercise of pre-funded warrants
Exercise of pre-funded warrants , shares 9,231              
Treasury stock obtained in exchange for return of investment interest to Compedica (20) (20) (20)
Treasury stock obtained in exchange for return of investment interest to Compedica , shares (625)              
Put rights exercised and return of shares
Put rights exercised and return, shares (123)              
Ending balance, value at Mar. 31, 2026 $ 266,053 $ 25,275 $ (20) $ (284,079) $ 7,229 $ (705) $ 6,524
Ending Balance, shares at Mar. 31, 2026 23,470